Wall street… tweaks
The analog of psilocybin that Gilgamesh is developing has been designed to eliminate the hallucinogenic experiences that are often set off by so-called magic mushrooms. Researchers working with the company [including team members from ATAI, Pfizer, Johnson & Johnson, etc], administer test drugs [new chemical entities] to mice and then capture their reactions using video cameras positioned above their cages… use tiny silicon probes known as neuropixels… implanting neuropixels into rodent brains…
The 64-year-old psychiatrist-turned-entrepreneur disdains the approach taken by other startups for several reasons. First, without intellectual-property protection, he says, companies will find it all but impossible to raise enough money to commercialize a therapy based on an existing psychedelic drug in the public domain… “If any optimization has been done, it’s been done on the gray market and not to generate a therapeutic effect.”
Original Article (Lucid News and Wall Street Journal):
Wall street backs new class of psychedelic drugs & Gilgamesh tweaks known psychedelics to improve therapies
Artwork Fair Use: Leepower
Recent Comments